Leap Therapeutics announced it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 12,660,993 shares of its common stock at a price of $2.82 per share and pre-funded warrants to purchase 1,523,404 shares of common stock at a price of $2.819 per share of common stock issuable upon exercise of the pre-funded warrants, in a private placement. Leap anticipates the gross proceeds from the private placement will be approximately $40M, before deducting any offering-related expenses. The financing is expected to close on April 15, subject to satisfaction of customary closing conditions. The private placement investors included new and existing investors, including Gilead Sciences, Samsara BioCapital, 683 Capital Partners, LP, Laurion Capital Management, and Rock Springs Capital. J.P. Morgan acted as the exclusive placement agent for the transaction.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LPTX:
- Leap Therapeutics price target lowered to $9 from $11 at Baird
- Leap Therapeutics’ Success Tied to Partner NovaRock’s Commitment in Asian Markets
- Leap Therapeutics files $200M mixed securities shelf
- Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- Leap Therapeutics reports Q4 EPS (46c), consensus (55c)